STLAM:MIL

Stellantis N.V.

Data as of 2026-03-11 - not real-time

€6.06

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Stellantis shares are trading well below their twentieth‑day and fiftieth‑day moving averages, underscoring a bearish price bias.
The relative strength index sits in the mid‑thirties, suggesting the stock is approaching oversold territory. A bullish MACD histogram provides a modest counter‑signal, but the overall trend remains down. Volatility is exceptionally high, reflecting large price swings day‑to‑day. The beta is modest, indicating limited sensitivity to broader market moves. The dividend yield sits in the double‑digit range, making the stock attractive to income seekers. Fundamental metrics reveal weak profitability, with operating and net margins in negative territory. Cash generation is negative, and free cash flow remains deeply in the red, raising concerns about the sustainability of the generous payout. Leverage is elevated, with debt far exceeding equity, while the price‑to‑book ratio is well under one, hinting at a potentially undervalued balance sheet. Forward earnings multiples are low, suggesting the market has priced in a steep earnings recovery. Recent news of exiting the Samsung battery joint venture and a reset of EV plans signal strategic retrenchment amid mounting electric‑vehicle losses. An upgrade to a buy rating by a boutique firm, despite a reduced price target, reflects optimism that the restructuring could unlock value.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near support level
  • oversold RSI reading
  • attractive dividend yield

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • potential undervaluation relative to book
  • strategic EV and battery restructuring
  • upgraded analyst rating

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • persistent negative cash flow
  • high leverage and debt load
  • uncertain dividend sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth10.30%
Profit Margin-14.57%
P/E Ratio3.8
ROE-32.81%
ROA-1.91%
Debt/Equity85.15
P/B Ratio0.3
Op. Cash Flow€-4649999872
Free Cash Flow€-8941500416

Technical Analysis

TrendBearish
RSI35.8
Support€5.92
Resistance€6.96
MA 20€6.48
MA 50€7.66
MA 200€8.42
MACDBullish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Target Price€8.28
Upside/Downside36.68%
GradeUndervalued
TypeValue
Dividend Yield11.13%

Risk Assessment

Beta0.70
Volatility96.14%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.